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Cannabis for Medical Use 
Information for Patients and healthcare professionals. 
 
• Introduction 
The following information is for healthcare professionals, patients and others who are 
interested in finding out more about cannabis for medical use. It will discuss current and 
proposed access to potential cannabis treatment and describe the legal and policy status of 
cannabis.  It also describes the Minister for Health’s role in relation to access to cannabis for 
medical use, as provided for in the Misuse of Drugs Acts 1977-2016 and in line with expert 
clinical and scientific advice. 
Cannabis and cannabis-based products which do not have a marketing authorisation are not 
medicines as defined under national and European legislation. As such, they are not subject to 
the same rigorous safety, quality and efficacy standards that are in place for medicines, nor are 
the producers subject to the same responsibilities as the marketing authorisation holders for 
authorised medicines. 
This document refers only to cannabis for medical use. Other matters related to cannabis 
including recreational use, decriminalisation, non-medical research, manufacturing, 
growing/producing cannabis or any other cannabis-related matters should be considered 
separate and distinct from the information below. 
  
• Background and Policy Context to use of cannabis for medical purposes in 
Ireland 
There is considerable public interest in the use of cannabis for medical purposes. While the 
medical potential of cannabis is clearly of interest and potentially promising, the quality of the 
evidence reported so far is limited. 
A Health Products Regulatory Authority (HPRA) review in 2017 concluded that the available 
scientific evidence found, at best, a moderate benefit for cannabis in a small number of medical 
conditions. 
  
• Differences between the main active components of cannabis - THC and CBD 
The two active components of cannabis that are of current medical interest are 
tetrahydrocannabinol (THC) and cannabidiol (CBD). 
 
 
THC 
THC is the main psychoactive constituent of cannabis. Under the Misuse of Drugs legislation, 
products containing THC are strictly controlled and possession is unlawful, except under 
Ministerial licence. 
CBD 
CBD is also derived from cannabis; however, as it is not psychoactive, it is not controlled under 
the Misuse of Drugs legislation. Products containing only CBD therefore do not require a 
Ministerial licence for use. 
  
• Legal and policy position on access to cannabis for medical use 
The Misuse of Drugs Acts 1977 to 2016, and enabling Regulations, set out the controls and 
restrictions that apply to cannabis in Ireland. 
Under the Misuse of Drugs Regulations 2017, cannabis and products or preparations extracted 
from the cannabis plant which are psychoactive are listed in Schedule 1. This means that it is 
subject to the strictest level of control; however, under this legislation it is open to the Minister 
for Health to consider granting a licence to an Irish-registered medical practitioner for 
medical cannabis for a named patient. It is important to note that a licence cannot be granted 
in relation to the provision of cannabis for medical use to a patient in their own name. 
The Chief Medical Officer has advised that the granting of a licence must be based on an 
appropriate application being submitted by an Irish-registered medical practitioner to the 
Minister for Health. The application must be endorsed by the patients’ medical consultant who 
is responsible for the management of the patient and who is prepared to monitor the effects of 
the medical cannabis treatment over time. 
Neither the Minister, nor the Department of Health can make the clinical decision that 
medical cannabis would be appropriate for the treatment of an individual’s health. The 
safety and efficacy of cannabis in a large number of medical conditions has yet to be proven. 
Such products should only be considered for use, after consultation with an individual’s 
medical advisors and where conventional/existing, evidence-based treatments or therapies 
have proven unsuccessful or inappropriate for the patient. 
It will always be the decision of the clinician, in consultation with their patient, to prescribe or 
not prescribe a particular treatment, including cannabis-based treatments, for a patient under 
their care. The Minister for Health has no role in this clinical decision-making process. 
 
 
 
 
• Medical cannabis clinical guidelines 
Disclaimer 
This Clinical Guide does not replace professional judgment on particular cases, whereby the 
clinician or health professional decides that individual guideline recommendations are not 
appropriate in the circumstances presented by an individual patient, or whereby an 
individual patient declines a recommendation as a course of action in their care or treatment 
plan. In these circumstances the decision not to follow a recommendation should be 
appropriately recorded in the patient’s healthcare record. 
Users of the information pertaining to medical cannabis in these webpages and in the 
Clinical Guide on medical cannabis must ensure they have the current version (hardcopy 
or softcopy) by checking the relevant section in the Department of Health website. 
 
Clinical guidelines for prescribers have been drawn up by an expert group of doctors, 
pharmacists, patient representatives and scientific experts, to support the Medical Cannabis 
Access Programme, which is currently under development. These clinical guidelines are 
available here.   
While these guidelines will primarily underpin the functioning of the Access Programme, the 
Department invites all clinicians with an interest in considering use of a cannabis-based 
treatment for their patient to review the information contained within. 
As the guidelines were drawn up by an expert group from a range of healthcare and research 
disciplines, it is also suggested that clinicians who wish to apply to the Minister for Health for 
a licence to use cannabis for medical purposes for indications which are outside of the Access 
Programme should refer to the guidelines before submitting their application. 
  
• Applying to the Minister for Health for a medical cannabis licence  
Where an Irish-registered medical practitioner wishes to consider using cannabis as a treatment 
for their patient, a licence can be requested from the Minister for Health. In all cases, certain 
strict conditions must be met in order for such a request to be considered valid. 
  
• Who can apply for a medical cannabis licence 
It is important to note that cannabis for medical use licence applications can only be accepted 
by the Minister for Health from: 
• an individual patient’s medical consultant, where evidence of an established doctor-
patient relationship exists, 
or 
• from the individual patient’s General Practitioner (GP) where the GP’s licence 
application is accompanied by a written endorsement for the cannabis treatment from 
the patient’s medical consultant. 
To see the requirements for the granting of a Ministerial licence and information on how to 
apply please see the Ministerial Licence Application Process section below. 
  
• Medical Cannabis Access Programme  
The Minister intends to introduce a Cannabis for Medical Use Access Programme. This 
programme is under development and it will facilitate access to cannabis products, which are 
not authorised as medicines, for patients suffering from a limited number of medical conditions. 
  
• Difference between cannabis-based medicines and cannabis-based products 
Under Irish and EU law, medicinal products (medicines) are required to be authorised before 
they are placed on the market. Medicinal products must demonstrate their quality, safety, and 
effectiveness based on clinical trial data in order to receive their authorisation.  Authorisations 
are issued by either a national competent authority such as the HPRA or by the European 
Medicines Agency.  Authorised medicines have a positive benefit/risk profile and are subject 
to on-going monitoring by regulatory authorities. 
This section will explain the difference between an authorised cannabis-based medicine and a 
product derived from cannabis which is not authorised but which may be considered for 
inclusion as part of a patient’s medical treatment. 
  
• Cannabis-based medicines 
Authorised cannabis-based medicines are manufactured from standardised extracts of the 
cannabis plant or created as synthetic analogues of specific cannabinoids. Authorised cannabis-
based medicines have demonstrated their quality, safety, and effectiveness based on clinical 
trial data.  They have a positive benefit/risk profile and are subject to on-going monitoring by 
regulatory authorities, such as the HPRA. 
To date one cannabis-based medicine, Sativex, has been authorised in Ireland and is indicated 
for the treatment of spasticity related to Multiple Sclerosis. Prescribing of Sativex does not 
require a ministerial licence, under the Misuse of Drugs Acts. 
Two other medicines, which have been developed based on the chemical structure of THC, 
have been authorised in some countries. 
1. Nabilone, a synthetic analogue of THC, is authorised for controlling nausea and 
vomiting associated with chemotherapy, in patients who have failed to respond 
adequately to conventional antiemetic therapies. In Ireland, Nabilone is listed in 
Schedule 2 of the Regulations and is therefore not subject to the same prohibitions as 
the cannabis plant. It can be prescribed without Ministerial licence. 
 
2. Dronabinol, a synthetic version of THC, is authorised for stimulating appetite in 
patients with AIDS-related wasting and for nausea and vomiting associated with 
chemotherapy. Dronabinol is listed in Schedule 1 of the Regulations and is therefore 
subject to the strictest level of controls and requires a Ministerial licence to facilitate it 
being prescribed. 
  
Medicines, authorised in Ireland or elsewhere, including authorised cannabis-based medicines, 
should be used in the first instance. However, if an authorised medicine is not available or is 
not suitable for the patient, cannabis-based products that do not have a marketing authorising 
may be considered as a treatment option, via the Ministerial licence application process, or 
eventually through the Medical Cannabis Access Programme, once it is established. 
  
• Cannabis-based products 
Cannabis-based products that do not have a marketing authorisation are not medicines as 
defined under national and European legislation. As such, they are not subject to the same 
rigorous safety, quality and efficacy standards that are in place for medicines, nor are the 
producers subject to the same responsibilities as the marketing authorisation holders for 
authorised medicines. 
 Whilst efficacy and safety data are not available for these products, it is important to be 
assured, as far as possible, of the quality of the products. These products will be required to 
be made to specified laboratory and manufacturing standards and are often supplied in the 
form of processed oils or sprays with identified levels of the cannabinoids required. 
  
• Availability 
Medical cannabis products that meet accepted quality standards have not, as yet, been made 
available by producers directly to the Irish marketplace. This is a critical aspect of facilitating 
access to medical cannabis for Irish-based patients. Department of Health officials are working 
intensively to ensure a supply of appropriate cannabis-based medical products to meet the 
needs of Irish patients 
  
 
Glossary of terms 
• Cannabinoid - any of a group of closely related compounds which include cannabinol 
and the active constituents of cannabis. 
  
• Tetrahydrocannabinol - also known as THC - A psychoactive cannabinoid which is 
strictly controlled under the Misuse of Drugs Act. 
  
• Cannabidiol – also known as CBD - A non-psychoactive cannabinoid which is not 
subject to control under the Misuse of Drugs Act and which is sometimes sold as a food 
supplement. 
  
• Health Products Regulatory Authority (HPRA) - the Competent Authority for the 
implementation of EU and national legislation relating to medicines in Ireland. The 
HPRA’s role includes monitoring and inspecting health products on the market to 
ensure their safety, efficacy and legality. 
  
• Psychoactive Substance - a substance having a profound or significant effect on 
mental processes. 
  
• Misuse of Drugs Acts and Regulations - The Misuse of Drugs Acts and the 
Regulations made thereunder are the main laws regulating controlled drugs in Ireland. 
They include controls relating to cultivation, licensing, possession, administration, 
supply, record-keeping, prescription-writing, destruction, storage and safe custody, 
import and export. They also establish the offences and penalties under the Act. 
 
 
 
 
 
 
Ministerial Licence Application Process 
 
 
This section contains more detailed information for clinicians who require information about 
the Ministerial licence application process for cannabis-based treatments. 
• Under the Misuse of Drugs Act, it is open to the Minister for Health to consider granting 
a licence to an Irish-registered medical practitioner for access to cannabis for medical 
use for a named patient(s) under his or her care. 
• The Chief Medical Officer has advised that the granting of a Ministerial licence for 
medical cannabis must be based on an appropriate application being submitted to the 
Department of Health that is endorsed by a medical consultant who is responsible for 
the management of the patient and who is prepared to monitor the effects of the 
treatment over time. 
• A valid licence application under the Misuse of Drugs Acts must include 
• An outline of the treatment the patient has received to date and justification from the 
doctor as to why it is appropriate, in their patient’s specific circumstances, to prescribe 
cannabis. 
• Details of the cannabis-based product which it is proposed to prescribe and administer 
to the patient. 
• The source of the cannabis-based product. 
• The arrangements for the ongoing monitoring and care of the patient once the cannabis-
based treatment has commenced. 
It is important to note that it will always be the decision of the clinician, in consultation with 
their patient, to prescribe or not prescribe a particular treatment, including cannabis treatment, 
for a patient under their care. The Minister for Health has no role in this clinical decision-
making process. 
  
Note - The requirements for an application to use cannabis-based treatments are subject 
to change as the policy on cannabis for medical purposes continues to develop. 
Medical practitioners who wish to submit an application or who require further 
information should contact controlled_drugs@health.gov.ie 
Licence applications received by the Minister for Health are assessed by Department 
officials for compliance with the applicable provisions of the Misuse of Drugs Acts and to 
ensure they are in line with the advice provided to the Minister by the Chief Medical 
Officer on the matter. Licence applications are not clinically reviewed. It is the 
responsibility of the applicant to ensure the clinical appropriateness of the proposed 
medical cannabis treatment for their patient.  
 
"Neither the Minister, nor the Department of Health can make the clinical decision that 
medical cannabis would be appropriate for the treatment of an individual’s health. The 
safety and efficacy of cannabis in a large number of medical conditions has yet to be proven. 
Such products should only be considered for use, after consultation with an individual’s 
medical advisors and where conventional/existing, evidence-based treatments or therapies 
have proven unsuccessful or inappropriate for the patient." 
  
Application Process for a Ministerial Licence 
In order to ensure a Ministerial licence application submitted by a medical practitioner is valid, 
a template document is available here, which may be used as a guide in applying for a 
Ministerial licence. 
It is important to note that the Department of Health may request additional contact or 
particulars from an applicant before considering an individual application to be full and valid. 
All applications are treated individually and so processing time for each application may differ, 
however the Department considers all valid applications as priority correspondence and will 
endeavour to maintain as efficient a processing system as possible. 
Any personal data received as part of the application will be subject to the provisions of the 
General Data Protection Regulation (GDPR) and the Data Protection Acts.  To process the 
application fully it may be necessary to share personal data with the Health Service 
Executive.  In these circumstances the data will be shared for that one purpose only. 
For further information see the Department’s Privacy Statement. 
 
 
 
 
 
 
 
 
 
 
Medical Cannabis Access Programme 
 
 
In November 2016, the Minister for Health announced a review of policy on cannabis for 
medical purposes and requested the HPRA’s views on recent developments in the use of 
cannabis for medical purposes including products available, research, indications and evidence 
of effectiveness, an overview of the different regulatory regimes in place in countries which 
allow cannabis to be used for medical purposes and legislative changes that would be required 
to allow use of cannabis for medical purposes in Ireland. 
The HPRA established a Working Group of relevant experts to assist with its review. The 
experts included consultant neurologists, a consultant in palliative medicine, a consultant 
psychiatrist specialising in addiction, a consultant anaesthetist/pain specialist, and a palliative 
care pharmacist as well as patient representatives. 
The HPRA’s subsequent report ‘Cannabis for Medicinal Use – A Scientific Review’, published 
in February 2017, recommended that if access to cannabis is to be permitted for medical 
purposes, that its use should only be initiated as part of a structured process of formal on-going 
clinical evaluation in a limited number of clearly defined medical conditions which have failed 
to respond to all other previous treatments, and where there is at least modest evidence that 
cannabis may be effective. 
The report noted that all such patients should be under the direct supervision of an appropriately 
trained and experienced medical consultant. The specified medical conditions (medical 
indications) are: 
  
• Spasticity associated with multiple sclerosis resistant to all standard therapies and 
interventions whilst under expert medical supervision; 
  
• Intractable nausea and vomiting associated with chemotherapy, despite the use of 
standard anti-emetic regimes whilst under expert medical supervision; 
  
• Severe, refractory (treatment-resistant) epilepsy that has failed to respond to standard 
anticonvulsant medications whilst under expert medical supervision. 
  
The HPRA report further recommended the introduction of a monitored cannabis treatment 
programme and advised that such a programme is necessary, both to maximise the safe and 
effective use of cannabis as a medical therapy for an individual patient, and to minimise the 
potential negative impact of wider access on society. It is planned that the programme should 
run for a period of five years, with a centralised data collection point and regular reports to the 
Department of Health. This information will provide data on the medical use of cannabis and 
the supply needs in Ireland. 
On foot of the conclusions from the HPRA’s report, the Minister established an Expert 
Reference Group to advise on the development of a Medical Cannabis Access Programme. The 
Expert Reference Group is chaired by Dr Mairín Ryan, Director of Health Technology 
Assessment at the Health Information and Quality Authority (HIQA). The group comprises 
representation from the areas of Oncology, Palliative care, Anaesthesiology, General Practice, 
Adult Neurology, Paediatric Neurology, Multiple Sclerosis, Psychiatry, Pharmacy, Patients, 
Ethics, Health Technology Assessments and the Health Products Regulatory Authority. 
The Expert Group was asked to advise on the development of operational, clinical and practice 
guidelines for healthcare professionals treating patients through an Access Programme. An 
important aspect of the work of the Group was to engage with representative bodies, clinicians, 
patients, and pharmacists, all of whom are integral to the production of clinical and operational 
guides for an Access Programme. The Group also conducted a targeted consultation on the 
draft form of the clinical guide, which has been finalised and is available here.  
Expert stakeholder engagement is being undertaken to set the quality standards to be applied 
to medical cannabis products that will be permitted for use under the Access Programme. This 
will help to ensure that many of the quality controls expected for other medicines can be applied 
to medical cannabis. 
The Access Programme is not yet operational, as further work is required in relation to certain 
elements, in particular the availability of appropriate quality-approved medical cannabis 
products for patients. This is a critical aspect in establishing the access programme. The 
Department is working intensively on finding solutions to the supply of appropriate products 
for Irish patients. 
In the meantime, prescribing of cannabis for medical treatment by medical consultants, for 
their individual patients is being facilitated via the Ministerial licence application route. 
 
  
 
